Other mechanisms were revealed in studies involving other types of cancer, including bortezomib-induced upregulation of NK cell activating receptor ligands (MIC-A/B, ULBP-1) or ligands related to the death receptor signaling (Fas, DR-5) (308–310). This evidence concerns the gene NCR2 and cancer.